Feinstein Institute study looks at impact of a popular pre-heart transplant therapy on the kidney

October 25, 2017, Northwell Health's Feinstein Institute for Medical Research

Scientists, nephrologists and cardiac surgeons from The Feinstein Institute for Medical Research and Northwell Health's Department of Internal Medicine, Cardiology and Cardio-Thoracic Surgery examined the impact of a popular pre-heart transplant therapy on the kidney in a study published today by The Clinical Journal of the American Society of Nephrology. Better understanding how this therapy, called left ventricular assist device (LVAD), effects kidney function can improve outcomes and develop new treatment protocols as the device is growing in acceptance as a long-term treatment option.

LVAD's have been in use for more than 55 years as a temporary or "bridge" therapy for patients with congestive waiting for a heart transplant to maintain normal heart function. The device pumps blood from the left side of the heart to the right and then through the body. As the technology improves and the need for heart transplants is higher than available donor hearts, the LVAD has become a more permanent solution, requiring examination of long-term use. With kidney dysfunction being a known potential risk associated with LVADs, Feinstein Institute researchers felt it important to examine this relationship.

"More and more patients are surviving end-stage heart failure thanks to durable, implantable heart pumps, known as LVADs," said Gerin Rachel Stevens, MD, an author of the study and director of cardiomyopathy at Northwell Health, medical director of cardiomyopathy and cardiac transplantation at North Shore University Hospital and a Feinstein Institute scientist. "For those patients ineligible for heart transplantation, 'destination' or long-term LVADs improve both survival and quality of life, but it is important to understand how these devices impact the kidney. By understanding the risk factors for kidney injury, we can better evaluate LVAD candidates and put measures in place both before and after the device is implanted to help maintain the patient's health."

What researchers identified were a host steps, which when used in concert, could result in LVAD patients who enjoy improved outcomes. Some of the interventions posed in the study include having a nephrologist on the medical team pre-implantation, enhanced training for dialysis nurses in the function of LAVD's and identifying patients with prior to transplant.

"Knowledge of cardiac devices and their interaction with the is going to be of paramount importance for practicing nephrologists around the world," said Daniel W. Ross, MD, lead author and assistant professor at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, attending nephrologist for Northwell Health and Feinstein Institute scientist. "We hope this article serves as a reference for all renal physicians involved in the care of a cardiac patient with heart failure and spark ideas for future research."

Explore further: From heart failure to health: Pump shown to restore organ to fitness

Related Stories

From heart failure to health: Pump shown to restore organ to fitness

April 10, 2017
As we face a shortage of donated hearts for transplant, the study authors are calling for the devices to be considered as a tool which can allow patients to restore their health.

Drug therapy, LVAD helps severe heart failure patients recover function

November 13, 2016
More than a third of advanced heart failure patients treated with a combination of an artificial heart assist device, called a left ventricular assist device, or LVAD, and intensive drug therapy have recovered their heart ...

Heart failure patients, clinicians have differing perceptions of risk level

August 16, 2017
Physicians identified a majority of patients with advanced heart failure as at high risk for transplant, left ventricular assist device (LVAD) or death while few of those patients considered themselves to be at high risk, ...

Left ventricular assist device ups QoL in ambulatory heart failure

January 13, 2017
(HealthDay)—Left ventricular assist devices (LVADs) improve quality of life in ambulatory patients with advanced heart failure, but increase lifetime costs, according to a study published online Jan. 11 in JACC: Heart Failure.

LVADs may lead to declines in health, cognitive thinking in some heart failure patients

April 29, 2015
Left ventricular assist devices (LVADs) are life-prolonging devices for many patients with advanced heart failure but they also may leave some patients in poor health or with declines in brain function, according to two studies ...

Heart study aims to identify at-risk patients after pump implant

September 24, 2013
Emory researchers are exploring the use of echocardiography, an established non-invasive method to view the heart without radiation, to help identify patients at risk for right ventricular heart failure after implantation ...

Recommended for you

Natural antioxidant bilirubin may improve cardiovascular health

May 18, 2018
Bilirubin, a yellow-orange pigment, is formed after the breakdown of red blood cells and is eliminated by the liver. It's not only a sign of a bruise, it may provide cardiovascular benefits, according to a large-scale epidemiology ...

New algorithm more accurately predicts life expectancy after heart failure

May 17, 2018
A new algorithm developed by UCLA researchers more accurately predicts which people will survive heart failure, and for how long, whether or not they receive a heart transplant. The algorithm would allow doctors to make more ...

New genes found that determine how the heart responds to exercise

May 17, 2018
A new study by researchers at Queen Mary University of London and University College London (UCL) has discovered 30 new gene locations that determine how the heart responds to and recovers from exercise.

Novel therapy inhibits complement to preserve neurons and reduce inflammation after stroke

May 16, 2018
A team of investigators at the Medical University of South Carolina (MUSC) has developed a novel therapy for ischemic (clot-caused) stroke and has shown in a preclinical model that it locally inhibits complement at and around ...

Greater burden of atrial fibrillation linked to higher stroke risk

May 16, 2018
Among people with intermittently recurring atrial fibrillation who are not taking anti-blood-clotting medications, those whose hearts were in abnormal rhythms longer were three times more likely to have strokes or other types ...

Stroke prevention drug combo shows promise, study says

May 16, 2018
If you've had a minor stroke or a transient ischemic stroke (TIA), taking the clot-preventing drug clopidogrel along with aspirin may lower your risk of having a major stroke within the next 90 days, according to new research ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.